digiMedical Solutions, Inc. Pharmacy Chain Receives Certification Under Drug Enforcement Administration (DEA) Combat Methamphetamine Act Of 2005

Colleyville, TX - digiMedical Solutions, Inc. recently announced the company's pharmacy chain has received compliance certification under the Drug Enforcement Administration (DEA) The Combat Methamphetamine Act of 2005. The act requires all pharmacists and staff to be trained to spot customers purchasing any product containing pseudoephedrine, ephedrine, or phenylpropanolamine for the purpose of altering its chemical components to produce the street drug "Meth." Many popular over-the-counter medications such as Sudafed, Claritin-D, some Robitussin products and many house brands contain these chemicals, which are used as a decongestant for cold and allergy symptoms. Under the terms of the act, pharmacies are required to receive a customer signature for every product purchased containing the aforementioned chemicals. Additionally, pharmacists are required to monitor patients to ensure that they make no purchase more than 3.6 grams of substances containing these chemicals per day. To further aide in the prevention of "meth" abuse, these products will be kept behind the counter.

digiMedical currently owns and operates four pharmacies in South Florida under the name Harrington's Pharmacies and two pharmacies in Texas with a network of over 35,000 patients. In addition to owning and operating pharmacies in Florida and Texas, digiMedical Solutions is a Microsoft partner and has developed proprietary technologies and processes to digitally streamline the prescription handling process from physician to pharmacy, securely and quickly. digiMedical's technology solution is also ideal for managing Schedule II controlled substances to avoid the abuse of such drugs. digiMedical expects to report over $7.5M in revenue for 2006, and has forecasted $14.5M for 2007 revenue.

To be added to digiMedical's corporate e-mail list for shareholders and interested investors, please send an e-mail to ir@digimedical.com.

SOURCE: digiMedical Solutions, Inc.